Wells Fargo’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.66M | Sell |
89,406
-69,428
| -44% | -$2.08M | ﹤0.01% | 3055 |
|
|
2025
Q4 | $6.07M | Buy |
158,834
+84,151
| +113% | +$2.74M | ﹤0.01% | 2489 |
|
|
2025
Q3 | $1.78M | Buy |
74,683
+5,863
| +9% | +$110K | ﹤0.01% | 3394 |
|
|
2025
Q2 | $1.02M | Buy |
68,820
+2,753
| +4% | +$45.6K | ﹤0.01% | 3679 |
|
|
2025
Q1 | $1.18M | Buy |
66,067
+8,619
| +15% | +$175K | ﹤0.01% | 3547 |
|
|
2024
Q4 | $1M | Buy |
57,448
+17,716
| +45% | +$313K | ﹤0.01% | 3709 |
|
|
2024
Q3 | $556K | Sell |
39,732
-2,808
| -7% | -$29.3K | ﹤0.01% | 3926 |
|
|
2024
Q2 | $350K | Buy |
42,540
+8,433
| +25% | +$56.8K | ﹤0.01% | 4139 |
|
|
2024
Q1 | $263K | Buy |
34,107
+1,649
| +5% | +$13.9K | ﹤0.01% | 4295 |
|
|
2023
Q4 | $292K | Sell |
32,458
-63,372
| -66% | -$461K | ﹤0.01% | 4231 |
|
|
2023
Q3 | $857K | Sell |
95,830
-27,066
| -22% | -$382K | ﹤0.01% | 3429 |
|
|
2023
Q2 | $1.89M | Buy |
122,896
+52,518
| +75% | +$955K | ﹤0.01% | 2963 |
|
|
2023
Q1 | $1.58M | Buy |
70,378
+67,153
| +2,082% | +$1.43M | ﹤0.01% | 3054 |
|
|
2022
Q4 | $67.8K | Sell |
3,225
-2,123
| -40% | -$45K | ﹤0.01% | 4729 |
|
|
2022
Q3 | $131K | Buy |
5,348
+1,083
| +25% | +$28K | ﹤0.01% | 4470 |
|
|
2022
Q2 | $103K | Sell |
4,265
-38,265
| -90% | -$962K | ﹤0.01% | 4621 |
|
|
2022
Q1 | $1.1M | Sell |
42,530
-17,895
| -30% | -$475K | ﹤0.01% | 3809 |
|
|
2021
Q4 | $1.88M | Buy |
60,425
+14,319
| +31% | +$403K | ﹤0.01% | 3562 |
|
|
2021
Q3 | $1.12M | Sell |
46,106
-164,520
| -78% | -$3.02M | ﹤0.01% | 4150 |
|
|
2021
Q2 | $3.07M | Buy |
210,626
+59,518
| +39% | +$1.17M | ﹤0.01% | 3306 |
|
|
2021
Q1 | $3.77M | Buy |
151,108
+38,961
| +35% | +$1.08M | ﹤0.01% | 3110 |
|
|
2020
Q4 | $3.06M | Buy |
112,147
+14,948
| +15% | +$349K | ﹤0.01% | 3168 |
|
|
2020
Q3 | $1.79M | Buy |
97,199
+6,947
| +8% | +$135K | ﹤0.01% | 3406 |
|
|
2020
Q2 | $1.84M | Buy |
90,252
+67,390
| +295% | +$1.07M | ﹤0.01% | 3333 |
|
|
2020
Q1 | $333K | Sell |
22,862
-37,637
| -62% | -$566K | ﹤0.01% | 4348 |
|
|
2019
Q4 | $859K | Buy |
60,499
+36,680
| +154% | +$469K | ﹤0.01% | 3956 |
|
|
2019
Q3 | $276K | Buy |
23,819
+1,276
| +6% | +$21.1K | ﹤0.01% | 4767 |
|
|
2019
Q2 | $453K | Sell |
22,543
-45,805
| -67% | -$904K | ﹤0.01% | 4443 |
|
|
2019
Q1 | $1.55M | Sell |
68,348
-822
| -1% | -$18.2K | ﹤0.01% | 3558 |
|
|
2018
Q4 | $1.57M | Sell |
69,170
-41,415
| -37% | -$1.03M | ﹤0.01% | 3482 |
|
|
2018
Q3 | $3.18M | Buy |
110,585
+15,335
| +16% | +$438K | ﹤0.01% | 3020 |
|
|
2018
Q2 | $2.6M | Buy |
95,250
+19,216
| +25% | +$512K | ﹤0.01% | 3252 |
|
|
2018
Q1 | $1.7M | Sell |
76,034
-954
| -1% | -$22.7K | ﹤0.01% | 3496 |
|
|
2017
Q4 | $1.62M | Buy |
76,988
+18,314
| +31% | +$419K | ﹤0.01% | 3534 |
|
|
2017
Q3 | $1.46M | Buy |
58,674
+19,163
| +49% | +$422K | ﹤0.01% | 3561 |
|
|
2017
Q2 | $767K | Sell |
39,511
-11,274
| -22% | -$204K | ﹤0.01% | 3926 |
|
|
2017
Q1 | $938K | Buy |
50,785
+5,763
| +13% | +$113K | ﹤0.01% | 3801 |
|
|
2016
Q4 | $852K | Buy |
45,022
+7,292
| +19% | +$149K | ﹤0.01% | 3804 |
|
|
2016
Q3 | $844K | Buy |
37,730
+9,092
| +32% | +$173K | ﹤0.01% | 3592 |
|
|
2016
Q2 | $510K | Sell |
28,638
-1,450
| -5% | -$23.5K | ﹤0.01% | 3895 |
|
|
2016
Q1 | $410K | Buy |
30,088
+448
| +2% | +$6.8K | ﹤0.01% | 3995 |
|
|
2015
Q4 | $571K | Sell |
29,640
-314,529
| -91% | -$6.28M | ﹤0.01% | 3847 |
|
|
2015
Q3 | $6.97M | Buy |
344,169
+24,744
| +8% | +$733K | ﹤0.01% | 2073 |
|
|
2015
Q2 | $10.6M | Buy |
319,425
+318,292
| +28,093% | +$8.72M | ﹤0.01% | 1862 |
|
|
2015
Q1 | $27K | Buy |
1,133
+146
| +15% | +$2.23K | ﹤0.01% | 5261 |
|
|
2014
Q4 | $12K | Sell |
987
-692
| -41% | -$7.16K | ﹤0.01% | 5558 |
|
|
2014
Q3 | $15K | Buy |
1,679
+166
| +11% | +$1.95K | ﹤0.01% | 5431 |
|
|
2014
Q2 | $18K | Buy |
+1,513
| New | +$20.5K | ﹤0.01% | 5419 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Wells Fargo's TVTX Position: Q1 2026 in Review
Wells Fargo reduced its Travere Therapeutics (TVTX) stake by 44% in Q1 2026, selling an estimated $2.08M and leaving 89,406 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.
Wells Fargo first reported a position in TVTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $10.6M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Wells Fargo held 89,406 shares of Travere Therapeutics worth $2.66M as of Q1 2026.
- Wells Fargo sold 69,428 Travere Therapeutics shares in Q1 2026, an estimated $2.08M.
- Travere Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3055 holding.
- Wells Fargo first reported a position in Travere Therapeutics in Q2 2014 and has held it in 48 quarters since.
- Wells Fargo's Travere Therapeutics position peaked at $10.6M in Q2 2015.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.